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Background
Egg allergy is one of the most common food allergies of
childhood with an estimated prevalence of 2.6 %. Aller-
gic reactions to egg may vary from atopic dermatitis to
systemic anaphylaxis. Although traditionally the only
treatment is dietary avoidance, oral immunotherapy
(OIT) appears as a promising approach to induce egg-
tolerance. However, the immune mechanisms underly-
ing this treatment are largely unknown. The purpose of
this study was to compare the clinical and immune
responses against egg allergens of a pediatric population
candidate for an OIT protocol with a non-atopic popu-
lation of the same age range.
Methods
A group of 19 pediatric patients with egg allergy con-
firmed by egg-specific IgE levels and positive double
blind placebo controlled tests (DBPCT) was compared
with a group of 9 non-atopic children on an egg-con-
taining diet. The mean age of the egg-allergic patients
was 10.1 years compared with 6.2 years in the control
group. No significant differences regarding sex or age
were found between the two groups. In both groups,
PBMCs were isolated from peripheral blood and stimu-
lated during 7 days with 200 μg/mL of ovalbumin
(OVA). Culture supernatants were analyzed for IL-5, IL-
13, IL-1b, IFN-g, TNF-a and IL-10 production by Cyto-
metric Bead Array (CBA).
Results
During the DBPCT with pasteurized egg-white, 8 egg-
allergic patients had urticaria, 5 anaphylaxis, 4 experi-
enced digestive symptoms and 2 respiratory symptoms.
The mean positive dose in the DBPCT was 1.4 mL of
egg-white, within a range of 0.001-8 mL. Specific IgE
measurements revealed, on average, 71.0 kU/L for egg-
white, 31.7 kU/L for OVA and 45.6 kU/L for ovomucoid.
CBA results showed a significantly impaired produc-
tion of OVA-specific IFN-g (P<0.05), TNF-a (P<0.01)
and IL-10 (P<0.01) in egg-allergic patients when com-
pared with control children. In addition, a trend toward
higher OVA-specific IL-5 and IL-13 production was
found in egg-allergic patients.
Conclusion
Under the conditions studied, egg-allergic children
showed a significantly reduced Th1 and Treg cytokine
production upon stimulation with OVA in comparison
with non-atopic controls. Furthermore, a trend toward
the production of IL-5 and IL-13 was observed. The
clinical response to egg in the allergic group was
reflected in the T-cell responses to OVA and the evolu-
tion of the cytokine profile upon a OIT protocol might
provide a better understanding of the immune responses
involved in allergy and tolerance to egg.
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